Friday 6 November 2026
Export PROF’s income statement to Excel — free account
Profound Medical
PROF Healthcare Medical Devices
Profound Medical’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, up 50.7% from fiscal 2024.
- Revenue
- +85.9%
- EPS
- +18.8%
- Free cash flow
- +47.9%
- Total debt
- +0.71%
Quarter to September 2026, against a year earlier
7.12
0.24
+3.49%
Follow PROF
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 4 | 4 | 6 |
| (67.12%) | (70.59%) | (73.53%) | (87.04%) | ||
| (57.64%) | (57.92%) | (58.44%) | (64.68%) | ||
ROIC |
(230.01%) | (174.72%) | (137.78%) | (156.58%) | |
Return on Tangible Assets |
(60.20%) | (65.26%) | (65.09%) | (75.21%) | |
Average Days of Receivables |
163.25 | 182.81 | 183.86 | 169.79 | |
Free Cash Flow per Share |
(1.29) | (1.06) | (0.99) | (0.86) | |
Free Cash Flow |
(38.86) | (38.51) | (36.10) | (31.49) | |
Capital Expenditures |
(0.65) | — | — | — | |
| Other line items | |||||
Cash ROIC |
(29.74%) | (33.71%) | (38.99%) | (39.19%) | |
Accounts Receivable Turnover |
2.26 | 2.45 | 2.63 | 2.47 | |
Accounts Payable Turnover |
3.27 | 3.41 | 5.66 | 7.00 | |
Inventory Turnover |
0.67 | 0.69 | 0.57 | 0.66 | |
Average Days of Payables |
121.25 | 143.67 | 64.73 | 61.93 | |
Days of Inventory on Hand |
639.08 | 603.71 | 708.72 | 605.20 | |
Tax Rate |
0.01 | 0.01 | 0.01 | 0.00 | |
Research and Development Expense of Revenue |
127.94% | 111.88% | 107.96% | 88.86% | |
Selling, General and Administrative Expense of Revenue |
199.10% | 161.75% | 149.14% | 130.08% | |
Share Based Compensation of Revenue |
34.10% | 29.49% | 26.05% | 15.07% | |
Operating CF/Net income |
0.90 | 0.99 | 1.10 | 0.97 | |
Depreciation/Fixed assets |
0.80 | 0.73 | 0.88 | 1.11 | |
Capex/Depreciation |
(1.17) | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.53 | 0.52 | 0.53 | 0.65 | |
Operating CF per Share |
(1.26) | (1.06) | (0.99) | (0.86) | |
Capex per Share |
(0.02) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026